Theodore Alan Huizenga is SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 41,840 shares of RARE, which is worth approximately $1.82 Million. The most recent transaction as insider was on Dec 10, 2024, when has been sold 648 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 41.8K
0.97% 3M change
69.98% 12M change
Total Value Held $1.82 Million

Theodore Alan Huizenga Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 10 2024
SELL
Bona fide gift
-
648 Reduced 1.53%
41,840 Common Stock
Sep 16 2024
BUY
Grant, award, or other acquisition
-
700 Added 1.63%
42,251 Common Stock
Sep 03 2024
SELL
Open market or private sale
$5,113 $56.19 p/Share
91 Reduced 0.22%
41,551 Common Stock
Apr 16 2024
SELL
Payment of exercise price or tax liability
$592 $42.31 p/Share
14 Reduced 0.03%
41,366 Common Stock
Mar 01 2024
SELL
Open market or private sale
$18,332 $53.76 p/Share
341 Reduced 0.82%
41,380 Common Stock
Mar 01 2024
SELL
Payment of exercise price or tax liability
$6,496 $53.69 p/Share
121 Reduced 0.29%
41,721 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
13,950 Added 25.0%
41,842 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$63,000 $21.0 p/Share
3,000 Added 9.71%
27,892 Common Stock
Dec 20 2023
BUY
Grant, award, or other acquisition
-
1,000 Added 3.9%
24,614 Common Stock
Sep 07 2023
SELL
Open market or private sale
$85,806 $39.67 p/Share
2,163 Reduced 8.39%
23,614 Common Stock
Sep 07 2023
BUY
Exercise of conversion of derivative security
$42,000 $21.0 p/Share
2,000 Added 7.2%
25,777 Common Stock
Sep 01 2023
SELL
Open market or private sale
$36,510 $37.64 p/Share
970 Reduced 3.92%
23,777 Common Stock
May 09 2023
BUY
Exercise of conversion of derivative security
$63,000 $21.0 p/Share
3,000 Added 8.89%
30,747 Common Stock
Apr 16 2023
SELL
Sale (or disposition) back to the issuer
$6,914 $38.2 p/Share
181 Reduced 0.65%
27,520 Common Stock
Apr 16 2023
SELL
Payment of exercise price or tax liability
$534 $38.2 p/Share
14 Reduced 0.05%
27,701 Common Stock
Mar 01 2023
SELL
Open market or private sale
$4,565 $45.65 p/Share
100 Reduced 0.43%
23,048 Common Stock
Mar 01 2023
SELL
Sale (or disposition) back to the issuer
$60,851 $45.65 p/Share
1,333 Reduced 5.78%
21,715 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
7,590 Added 24.69%
23,148 Common Stock
Feb 28 2023
SELL
Open market or private sale
$27,732 $43.4 p/Share
639 Reduced 3.95%
15,558 Common Stock
Dec 21 2022
SELL
Open market or private sale
$89,282 $43.96 p/Share
2,031 Reduced 11.14%
16,197 Common Stock
Sep 01 2022
BUY
Grant, award, or other acquisition
-
1,000 Added 5.24%
18,094 Common Stock
Apr 16 2022
SELL
Open market or private sale
$11,161 $84.55 p/Share
132 Reduced 0.77%
16,914 Common Stock
Mar 01 2022
SELL
Open market or private sale
$56,161 $66.62 p/Share
843 Reduced 5.99%
13,229 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
3,710 Added 17.87%
17,046 Common Stock
Oct 14 2021
SELL
Open market or private sale
$11,360 $81.14 p/Share
140 Reduced 0.99%
14,072 Common Stock
TAH

Theodore Alan Huizenga

SVP, Chief Accounting Officer
Novato, CA

Track Institutional and Insider Activities on RARE

Follow Ultragenyx Pharmaceutical Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if
Any

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE